US 11,986,819 B2
Method for the preparation of biosynthetic device and their uses in diagnostics
Franck Molina, Les Matelles (FR); Alexis Courbet, Issy les Moulineaux (FR); and Francisco Santos Schneider, Montpellier (FR)
Assigned to SKILLCELL, Jarry (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris (FR); and CHU MONTPELLIER, Montpellier (FR)
Appl. No. 16/090,291
Filed by SKILLCELL, Jarry (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris (FR); and CHU MONTPELLIER, Montpellier (FR)
PCT Filed Apr. 13, 2017, PCT No. PCT/IB2017/000683
§ 371(c)(1), (2) Date Oct. 1, 2018,
PCT Pub. No. WO2017/178896, PCT Pub. Date Oct. 19, 2017.
Claims priority of application No. 16165189 (EP), filed on Apr. 13, 2016.
Prior Publication US 2019/0111422 A1, Apr. 18, 2019
Int. Cl. B01L 3/00 (2006.01); B82Y 5/00 (2011.01); B82Y 10/00 (2011.01); B82Y 15/00 (2011.01); G01N 33/543 (2006.01); G01N 33/573 (2006.01); G06N 3/00 (2023.01); G16C 99/00 (2019.01)
CPC B01L 3/5027 (2013.01) [B82Y 10/00 (2013.01); G01N 33/5432 (2013.01); G01N 33/573 (2013.01); G06N 3/002 (2013.01); G16C 99/00 (2019.02); B82Y 5/00 (2013.01); B82Y 15/00 (2013.01)] 7 Claims
OG exemplary drawing
 
1. A method for the diagnosis of, or prediction of the risk of, an insulin-resistance pathology in a patient, said method comprising:
a) obtaining a composition comprising at least one of:
(i) non-living vesicles comprising encapsulated leucine dehydrogenase enzyme and non-living vesicles comprising encapsulated glucose-1-dehydrogenase enzyme;
(ii) non-living vesicles comprising encapsulated leucine dehydrogenase enzyme and non-living vesicles comprising glucose oxydase enzyme;
(iii) non-living vesicles comprising encapsulated leucine dehydrogenase enzyme, non-living vesicles comprising encapsulted glucose-1-dehydrogenase enzyme, and non-living vesicles comprising encapsulated glucose oxydase enzyme;
(iv) non-living vesicles comprising both encapsulated leucine dehydrogenase enzyme and glucose-1-dehydrogenase enzyme;
(v) non-living vesicles comprising both encapsulated leucine dehydrogenase enzyme and glucose oxydase enzyme; and
(vi) non-living vesicles comprising encapsulated leucine dehydrogenase enzyme, glucose-1-dehydrogenase enzyme, and glucose oxydase enzyme;
b) brining into contact said composition comprising vesicles with a sample of the patient's blood, plasma, serum, and/or urine to generate two different output signals resulting from enzymatic reactions of the enzymes in the composition with components of the sample inside said vesicles, wherein the components comprise glucose and branched chain amino acids (BCAAs);
c) detecting or measuring the output signals generated at step b), said output signals being indicative of the levels of glucose and BCAAs and the diagnosis of, or prediction of the risk of, an insulin-resistnace pathology in said patient, wherein when the output signals indicate elevated levels of BCAA and glucose in the sample, the patient has, or is at risk of having, diabetes and when the output signals indicated elevated levels of BCAA but not elevated levels of glucose in the sample, the patient has, or is at risk of having, insulin resistance, wherein the BCAA and glucose levels are compared relative to standardized scales.